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An audit of topiramate use in a general neurology clinic 
PAMELA CRAWFORD 
Department of Neurosciences, York District Hospital, York Y03 7HE, UK 
The purpose of this study was to look at the efficacy and side effect profile of topiramate in a neurology unit. Using case notes, 
94 patients who had been treated with topiramate were identified: 48 patients had taken part in clinical trials of topiramate, 
46 received topiramate once licensed. Of these patients 24% had a greater than 50% decrease in seizure frequency. Patients 
with primary generalized epilepsy (n = 12) had a greater reduction in seizures compared with those with partial epilepsies 
(n = 70) P > 0.03. There was a high incidence (41%) of side effects, particularly psychiatric problems, leading to withdrawal of 
therapy in 41% of patients. Seven patients were admitted to hospital as a result of psychotic symptoms or depression. The incidence 
of psychotic symptoms (I 2%) was significantly higher for patients receiving topiramate compared with 191 patients attending 
the department on gabapentin (0.5%) and 270 patients attending the department on lamotrigine (0.7%) P‘ < 0.001. ‘Abnormal 
thinking’, consisting of mental slowing and word-finding difficulties, occurred in 31%. The incidence could be significantly 
reduced by using 25 mg dose increments fortnightly as opposed to 100 mg weekly (P > 0.03). Although topiramate is an 
effective antiepileptic drug, its use is accompanied by a high incidence of particularly psychiatric side effects. 
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INTRODUCTION 
Topiramate is a sulfanate-substituted monosaccharide’ 
that is a very effective antiepileptic drug in clinical stud- 
ies. The majority of randomized double-blind studies in 
patients with partial seizures have shown a greater than 
50% reduction in seizures in between 35%* and 47%3 
of patients treated with topiramate. However, there has 
been a high incidence of adverse events leading to ces- 
sation of therapy in many patients. 
An overview of double-blind randomized placebo- 
controlled studies has suggested that topiramate might 
be a very effective antiepileptic drug with an odds ra- 
tio of 50% responders of 4.22 (2.80-6.35). This was in 
association with a high dropout rate of 18% amongst 
360 patients4. 
Topiramate has been licensed as an add-on therapy 
for the treatment of partial epilepsies since October 
1995 in the UK. This retrospective study identified the 
patients who have been treated with topiramate in York 
prior to 1 January 1997 and looks at the effectiveness 
and the adverse effects of topiramate therapy in a gen- 
eral neurology outpatient clinic. 
MATERIALS AND METHOD 
All patients who had been treated with topiramate in 
York were identified by looking through the case notes 
of people attending the Department of Neurosciences, 
York District Hospital. All patients were under the care 
of a single consultant (P.M.C.). All patients were outpa- 
tients and living in the community. Ninety-four people 
were identified, 48 of whom had been in two intema- 
tional clinical trials with topiramate. The first study was 
an open label study of topiramate (TOP 107) as add- 
on therapy for drug-resistant epilepsy (36 patients), ei- 
ther partial or generalized. The second study was a 
double-blind placebo-controlled add-on study of topi- 
ramate (TOP 104) in patients with primary generalized 
epilepsy (12 patients), with an open label extension. 
The efficacy and side effect data were taken from the 
open-label extension study when all patients were re- 
ceiving topiramate. The other 46 patients were treated 
with topiramate once it had received its UK licence. All 
94 patients started treatment with topiramate at least 3 
months treatment prior to January 1997. The majority 
of patients were keeping seizure diaries and efficacy 
data are derived from these. The side effects recorded 
are those spontaneously reported by the patient or a 
carer. Results have been analysed using Fisher’s exact 
test, chi-squared test, Mantel Haenszel’s cm-squared 
test and Student’s r-test. 
RESULTS 
The patient demographic details are summarized in Ta- 
ble 1. The majority (765%) of the patients had the onset 
of epilepsy prior to the age of 18. Fourteen patients had 
1059-131 l/98/030207 + 05 $12.00/O CJ 1998 British Epilepsy Association 
208 P. Crawford 
Table 1: Patient demographics 
Age (years) Mean f SD 
Range 
Men 
Women 
Age at onset 
epilepsy (years) Mean f SD 
Range 
Type of epilepsy Localization-related 
Primary generalized 
Svmotomatic aeneralized 
36f 13 
12-75 
49 (52%) 
45 (48%) 
13 f 12 
O-58 
70 (74%) 
16 (17%) 
8 (9%) 
Table 2: Current antiepileptic drug therapy 
Mean 
dose f SD Dose range 
44 (77%) 
OWW) minm maxm 
Carbamazepine 993f319 400 1600 
Carbamazepine 
retard 
Phenytoin 
Sodium valproate 
Vigabatrin 
Lamotrigine 
Gabapentin 
Clobazam 
(regular dose) 
Clobazam PRN 
Clonazepam 
Acetazolamide 
Primidone 
Ttagabine 
Etbosuximide 
Remacemide 
I2 (13%) 1200 f 438 200 I600 
I7 (18%) 355 f 96 I50 500 
31 (33%) 1668 f 605 500 3000 
6 (6%) 2lOOf490 500 3000 
21 (23%) 250 f I04 100 400 
12 (13%) 2010 f 968 900 3600 
lO(ll%) l6f IO 
20 (22%) 10 
2 (2%) 3.8 f 0.75 
2 (2%) 625 
I(I%) 250 
I (I%) 32 
I (1%) 1000 
ICI%) 800 
10 
3 
250 
40 
4.5 
IO00 
Diazepam I (I%) 10 
Table 3: New drugs tried prior to topiramate therapy 
Dw No. of patients 
Vigabatrin 36 (39%) 
Lamotrigine 63 (67%) 
Gabapentin 40 (43%) 
Remacemide I2 (13%) 
Tiagabine II (12%) 
Oxcarbazepine I (1%) 
Losigamone 3 (3%) 
Levetircetam 1 (1%) 
Felbamate 1 (1%) 
learning disabilities. All had seizure disorders resistant 
to current drug therapy and were having one or more 
seizures of any type per week. They had in the past 
tried between two and 14 antiepileptic drugs with a 
mean &SD of 5.8 f 2.0. Thirty-one (33%) were at the 
start of topiramate therapy on monotherapy, 36 (38%) 
on two antiepileptic drugs, 25 (27%) on three drugs and 
one (1%) on four drugs. Current drug treatment prior to 
topiramate therapy is summarized in Table 2. The ma- 
jority (60%) of patients were taking carbamazepine, 
a third (33%) sodium valproate, 23% lamotrigine and 
18% phenytoin. Only eight (9%) patients had not tried 
one of the new antiepileptic drugs (vigabatrin, lamot- 
rigine or gabapentin) prior to topiramate therapy (Ta- 
ble 3). 
Dosing schedule 
The dosing schedule for topiramate differed through- 
out this study. In the initial open-label add-on study, 
patients were treated with a starting dose of 100 mg 
and weekly 100 mg increments. However, as this was 
accompanied by a high incidence of side effects, the 
dosage increments were reduced to a starting dose of 
50 mg/day with 50 mg weekly increments. A 25 mg 
tablet became available in August 1996 and since then 
patients have been started on 25 mg/day and the dose 
increased every fortnight by 25 mg. Nineteen (20%) pa- 
tients were started on 100 mg/day, 47 (50%) received 
50 mg increments and 28 (30%) 25 mg increments. The 
dose was increased until either side effects appeared or 
seizure control improved. The mean dose achieved was 
352 mgf216 mg/day. The doses obtained varied be- 
tween 25 and 900 mg/day (Table 4). Patients remained 
on treatment from 3 days to 51 months. Overall there 
was over 102 patient man years of treatment with top- 
iramate. 
Efficacy 
Twenty-two (24%) of patients treated with topiramate 
had a greater than 50% reduction in seizure frequency 
(Table 5). Three of these 22 patients were seizure-free 
for at least 3 months. Sixty-one (63%) patients were un- 
changed or worse as a result of topiramate therapy. One 
patient with myoclonic absence seizures and another 
with tonic-clonic seizures became seizure-free and are 
now driving. Patients with generalized epilepsies had 
a greater improvement in seizure frequency with eight 
(33%) having greater than 50% reduction in seizure 
frequency compared with those with partial seizures 
(14 patients (20%)) P < 0.03 (Mantel Haenszel chi- 
squared test). Patients with partial seizures who were 
in the open-label clinical trial currently show a greater 
but non-significant improvement with 11 (33%) pa- 
tients having a greater than 50% reduction in seizures 
compared with three (8%) non-study patients who re- 
ceived topiramate since it was licensed (Table 6). This 
may be partly due to a lower mean dose and a shorter 
time on topiramate (NS) (Table 7). 
Currently 45 (48%) patients are continuing on topira- 
mate. Forty-nine (52%) patients have withdrawn from 
therapy, 24 (26%) for inefficacy and 39 (41%) due 
to side effects. Two female patients, both of whom 
had a greater than 50% reduction in seizure frequency, 
stopped topiramate therapy as they wished to become 
pregnant. One of them has subsequently restarted top- 
iramate after the birth of her child, resulting again in a 
greater than 75% reduction in seizure frequency. 
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Table 4: Topiramate therapy 
All patients Partial epilepsies Symptomatic generalized Primary generalized 
No. of oatients 94 70 8 16 
Dose obtained (mg) It SD 352f216 343 *218 306 f 256 398: 173 NS 
range (mg/day) 25-900 25-900 25-700 25-600 
Length of treatment 
(mths) f SD 13f I3 I4Lt 14 6f6 15 * IO NS 
range (mths) 0.1-51.3 0.1-51.3 0.2-17 3-28 
Table 5: Efficacy of topiramate 
No. of patients 
All patients 
94 
Partial epilepsies 
70 
Symptomatic generalized 
8 
Primary generalized 
16 
Seizure-free 
49-99% decrease 
25-49% decrease 
No change 
Deterioration 
3 (3%) 111%) 0 2 (13%) 
19(21%) 13 (19%) 2 (25%) 4 (25%) 
I2 (13%) 8 (12%) I(l3%) 3 (19%) 
53 (56%) 42 (52%) 4 (50%) 7 (44%) 
7 (7%) 6 (9%) I(l3%) 0 
Patients with partial seizures vs. those with primary generalized epilepsies P < 0.03 (Mantel Haenszel chi-squared test). 
Side effects 
There was a high incidence of side effects leading to 
withdrawal of topiramate in 39 (41%) patients. The 
side effects encountered are summarized in Table 8. 
The commonest encountered side effects were psychi- 
atric. Seven patients were admitted to hospital as a re- 
sult of side effects from topiramate, six with psychotic 
symptoms and one with depression and anxiety, Eleven 
patients developed hallucinations and delusions, in- 
cluding severe psychoses in two patients, necessitating 
hospital admission and treatment with major tranquil- 
lisers. Two patients developed symptoms of depression 
and another three people had symptoms of depression 
and auditory and visual hallucinations. One of the pa- 
tients who developed auditory and visual hallucinations 
on topiramate had previously had a similar problem 
when taking lamotrigine. Another patient, who needed 
a psychiatric referral because of severe depression and 
auditory hallucinations, had a diagnosis of Asperger’s 
syndrome. A third patient, who developed visual and 
auditory hallucinations and depression whilst taking 
topiramate, has since gone on to develop a mild de- 
mentia secondary to cerebrovascular disease. The rest 
had no past history of significant psychiatric illness. 
The other psychiatric side effects were more minor and 
included anxiety, agitation and behavioural problems. 
Another commonly reported side effects (3 1%) was 
‘abnormal thinking’. This consisted of mental slow- 
ing in association with word-finding difficulties. The 
incidence fell from 53% in those who had 100 mg in- 
crements weekly (19 patients), via 28% for those with 
50 mg increments (47 patients) to 21% in those with 
fortnightly 25 mg increments (28 patients) P < 0.03 
(chi-squared test). This has resulted in a reduction in 
the drop-out rate due to side effects from 47% to 36%. 
Drowsiness (26%) was commonly reported, as was 
weight loss (18%). Paraesthesiae occurred in 8%. 
Speech disturbances were reported by 6% of patients. 
This consisted of difficulty in finding the correct words 
and was in association with slowing of cognitive func- 
tion. 
Renal problems are amongst the rare but well rec- 
ognized side effects of topiramate. One patient had an 
episode of pyelonephritis and another renal colic sec- 
ondary to renal calculi, subsequently demonstrated by 
ultrasound. 
DISCUSSION 
Topiramate undoubtedly is an effective antiepileptic 
drug with 23% of patients attending the outpatient 
clinic in this study having a decrease in seizure fre- 
quency by 50% or more. However, the results obtained 
in this study are much poorer than in the double-blind 
studies’*J-6, reflecting the difficulty in treating and 
improving seizure control in the majority of people 
with continuing seizures attending neurology outpa- 
tient clinics. People entering clinical trials are highly 
selected and often unrepresentative of the population 
with drug-resistant epilepsy as many of the latter group 
have additional handicaps. In the double-blind studies 
in patients with partial seizures, between 35%’ and 
47%3 had a greater than 50% reduction in seizure fre- 
quency. The majority of people in this report had the 
onset of their epilepsies in childhood and all patients 
had at least weekly seizures which had not responded 
adequately to currently available antiepileptic drugs. 
Such patients constitute a group with a poor prognosis 
for improvement in seizure control. AI1 but eight pa- 
tients had previously received one of the newly licensed 
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Table 6: Efficacy of topiramate in partial seizures: open-label study vs. non-study patients 
Partial epilepsics Study patients 
No. of patients 70 33 
Seizure-free l(l%) I (3%) 
49-99% decrease 13 (19%) IO (30%) 
2549% decrease 8 (12%) 4(120/n) 
No change 42 (52%) I3 (41%) 
Deterioration 6 (9%) 5 (15%) 
No. continuing on topiramate 33 (48%) I2 (36%) 
Drop outs 
Non-study patients 
37 
0 
3 (8%) 
4(11%) 
29 (76%) 
I (3%) 
21 (57%) 
side effects 
inefficacy 
31 (45%) I6 (48%) 15 (41%) 
21 (30%) I I (33%) IO (27%) 
Table 7: Topiramate therapy in patients with partial seizures 
Partial epilepsies 
No. of patients 70 
Dose obtained (mg) f SD 343 ZII 218 
range (mg/day) 25-900 
Length of treatment (mths) f SD l4f I4 
range (mths) 0.1-51 
Non-study patients Study patients 
37 33 
301 f 203 398 f 224 
25-800 50-900 
6f4 22f I7 
0.1-14 0.2-S I 
NS 
Table 8: Side effects of topiramate 
No. of patients 
Total nb. of side effects reported 
mean per patient 5 SD 
range 
Commonly reported side effects 
Psychiatric problems 
Psychotic symptoms 
Depression 
‘Abnormal thinking’ 
Drowsiness 
Weight loss 
Poor memory 
Headaches 
Dizziness 
Parasthesiae 
Speech disturbance 
Insomnia 
Unsteadiness 
Renal problems 
All patients 
94 
249 
4 f 2.3 
I-12 
Panial seizure patients 
Study patienb Non-study patients 
33 37 
II7 
4.3 f 2.2 
l-12 
60 
3.0 f I .9 
l-7 
38 (41%) 
I I (12%) 
5 (5%) 
29 (31%) 
24 (26%) 
17 (18%) 
I3 (14%) 
I2 (13%) 
9 (10%) 
8 (9%) 
8 (9%) 
6 (6%) 
6 (6%) 
2 (2%) 
14 (42%) 
5 (15%) 
2 (6%) 
I4 (42%) 
10 (30%) 
7 (21%) 
8 (24%) 
5 (15%) 
5 (15%) 
4(12%) 
4(12%) 
I (3%) 
2 (6%) 
2 (6%) 
I5 (41%) 
4(ll%) 
2 (5%) 
9 (24%) 
7 (19%) 
5 (14%) 
I (3%) 
J(II%) 
I (3%) 
2 (5%) 
2 (5%) 
2 (5%) 
4(ll%) 
0 
Doubl; vision 3 (3%j 0 I (3%) 
drugs in the UK (vigabatrin, gabapentin or lamotrigine) 
or trial antiepileptic drugs. Patients with partial seizures 
who had not been entered into the open-label clinical 
trial had much poorer efficacy results (8% vs. 33%) 
than the study patients. This may in part be due to a 
lower mean dose and a shorter period on topiramate 
although this did not reach statistical significance. 
Interestingly, although topiramate is currently only 
licensed as add-on therapy in patients with drug- 
resistant partial seizures, people with primary general- 
ized epilepsies showed a significantly greater reduction 
in seizure frequency suggesting that topiramate may be 
a broad spectrum antiepileptic agent, effective for both 
partial and generalized epilepsies. 
The most worrying aspect of topiramate has been its 
side effect profile, leading to withdrawal of the drug in 
41% of patients. Seven (7%) patients were admitted to 
hospital because of probable drug-related side effects, 
six with psychotic symptoms and one with depression 
and anxiety. Hallucinations, either visual or auditory, 
occurred in 11 (12%) patients. A high incidence of psy- 
chosis of between 1.4%7 and 8%s has been reported 
in people with epilepsy attending neurology outpatient 
clinics, particularly in those with partial seizures9. In 
an overview of the side effects of topiramate, a 3% 
incidence of psychosis and a 15% incidence of depres- 
sion is reportedlo. However, in patients attending the 
neurology outpatient clinic in York, psychosis has been 
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a relatively rare occurrence in patients started on new 
antiepileptic drugs. No patients started on vigabatrin 
(n = 88) developed psychotic symptoms, one (0.5%) 
patient on gabapentin (n = 191) and two (0.8%) on 
lamotrigine (n = 246). No York patient has been ad- 
mitted with drug-related side effects from these three 
drugs in the last 6 years. 
Depression, agitation and behavioural problems 
were also common amongst patients treated with top- 
iramate. Thirty-one percent of patients developed the 
problem of ‘abnormal thinking’ which consists of men- 
tal slowing and word-finding difficulties which seems 
to be a unique side effect of topiramate. Earlier arti- 
cles on topiramate suggested that slower and smaller 
dosage increases might result in a lower incidence of 
this problem 3*6*‘o This study has added further evi- . 
dence, with a significant reduction in this side effect 
using 25 mg increments fortnightly (P < 0.03). Inter- 
estingly, the incidence of psychiatric side effects was 
not altered by the slower dosing regime. The problem 
of ‘abnormal thinking’ has led to two patients being un- 
able to continue in employment, despite improvements 
in seizure control. 
This study confirms that topiramate is an effective 
antiepileptic drug. However, it does not need to be used 
with caution because of the high incidence of side ef- 
fects. 
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